Video

Sex differences in MS: It’s the chromosomes, not just the hormones


 

REPORTING FROM ACTRIMS FORUM 2019

– Hormonal differences are not the only reason that multiple sclerosis (MS) disease progression and severity differ between the sexes, according to Rhonda Voskuhl, MD, who delivered the Kenneth P. Johnson Memorial Lecture at a meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis.

“Sex differences in disease are widely prevalent across immunological and neurological diseases. For example, lupus affects women 9:1 more frequently, rheumatoid arthritis is about 3:1, and MS is 3:1,” said Dr. Voskuhl, director of the MS program and Jack H. Skirball Chair of Multiple Sclerosis Research at the University of California, Los Angeles.

However, although women are more likely to experience these diseases, men are often more severely affected by them, Dr. Voskuhl said. “Sometimes in neurodegenerative diseases like MS, we’re seeing that the men, although they get it less frequently, they do worse. ... So these are actually two very important sex differences in disease, one affecting susceptibility and frequency, and the other affecting how they do over the long run with respect to their progression and severity.”

This clinically apparent observation, known for decades, prompted Dr. Voskuhl and others to parse why sex differences exist in this gamut of diseases.

A novel animal model – the four-core genotype mouse model – has allowed Dr. Voskuhl and others to discern the contributions of hormonal versus chromosomal influences on disease susceptibility and progression. The model separates the sex chromosome complement (XX or XY) from gonadal influences, and it’s been extremely helpful in revealing the surprising influence that sex chromosomes play in MS and similar diseases, said Dr. Voskuhl in an interview.

Dr. Voskuhl is also the president-elect of the Organization for the Study of Sex Differences.

Recommended Reading

MS cognitive decline buffered by early high vitamin D levels
Journal of Clinical Outcomes Management
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
Journal of Clinical Outcomes Management
DMTs, stem cell transplants both reduce disease progression in MS
Journal of Clinical Outcomes Management
Early intensive treatment of MS may benefit patients
Journal of Clinical Outcomes Management
Large survey reveals that few MS patients have long-term care insurance
Journal of Clinical Outcomes Management
Incidence of treated depression nearly 100% higher in patients with MS
Journal of Clinical Outcomes Management
Migraine associated with more severe disability in patients with MS
Journal of Clinical Outcomes Management
MS research: “Our patients can’t wait” for conventional techniques
Journal of Clinical Outcomes Management
MS prevalence estimates reach highest point to date
Journal of Clinical Outcomes Management
Which comorbidities most diminish quality of life in patients with MS?
Journal of Clinical Outcomes Management